Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Harmony Biosciences (HRMY) and raises the price target from $50 to $52.

May 01, 2024 | 9:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Harmony Biosciences and raises the price target from $50 to $52.
The increase in price target by a reputable analyst like Ami Fadia from Needham is a strong positive signal for Harmony Biosciences. It suggests confidence in the company's future performance and growth prospects, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100